Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionHuman HuCAL neutralizing antibody against Dickkopf homolog 1 (DKK1)
Molecular Target Dickkopf homolog 1 (DKK1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM); Treat smoldering multiple myeloma; Treat tumor induced osteolytic bone disease in multiple myeloma (MM) patients
Regulatory Designation
PartnerMorphoSys AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today